TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Cero Therapeutics Holdings, Inc.
CERo Therapeutics Announces Receipt of Nasdaq Panel Determination

CERo Therapeutics has been denied continued listing on Nasdaq due to non-compliance with stockholders' equity requirements. The company plans to appeal the decision, seek OTC Markets trading, and continue clinical operations while exploring financing alternatives.

Insights
CERO   negative

Company faces Nasdaq delisting, potential funding challenges, and uncertainty about future trading platforms, which negatively impacts investor confidence and stock value